Ovarian cancer (OC) is a relatively fatal female reproductive malignancy. Since the underlying causes are uncertain, it brings us to believe that both genetic and external factors contribute toward development of this lethal disorder. Exposure to endocrine-disrupting chemicals (EDCs) in the form of occupational usage of pesticides, fungicides, herbicides, plasticizers, cosmetics, and so on is potentially carcinogenic and their ability to cause epigenetic modifications has led us to hypothesize that they may play a catalytic role in OC progression. In response to synthetic chemicals, animal models have demonstrated disturbances in the development of ovaries and steroid hormonal levels but in humans, more research is required. The present review is an attempt to address the impact of EDCs on the hormonal system and gene methylation levels that may lead to malfunctioning of the ovaries which may consequently develop in the form of cancer. It can be concluded that endocrine disruptors do have a potential carcinogenicity and their high proportions in human body may cause epigenetic modifications, prompting ovarian surface epithelium to grow in an abnormal manner.
TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalA. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2.
BergmanAHeindelJJJoblingSKiddKAZoellerRTJoblingSK. State of the science of endocrine disrupting chemicals. Geneva: United Nations Environment Programme and World Health Organization. ISBN:978 92 4 150503 1.2012.
3.
TengZHanRHuangX. Increase of incidence and mortality of ovarian cancer during 2003-2012 in Jiangsu Province, China. Front Public Health. 2016;4:146.
4.
CoburnSBBrayFShermanMETrabertB. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–2460. doi:10.1002/ijc.30676.
5.
FerlayJSoerjomataramIDikshitR. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
6.
StanculeanuDLMosoiuDMihneaASimionL. Actualities in ovarian cancer in the perspective of 2015 (ASCO and ECCO). Chirurgia. 2016;111(1):9–11.
7.
American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society; 2017Accessed April 9, 2017.
8.
StewartSL. Ovarian cancer incidence: current and comprehensive statistics. In: SamirF, ed. Ovarian Cancer-Clinical and Therapeutic Perspectives. Europe: InTech; 2012: 1–15.
9.
JoungKHJeongJWKuBJ. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int. 2015;2015:12.
10.
AnandPAjaikumarBKSundaramC. Cancer is a preventable disease that requires major lifestyle changes. Pharma Res. 2008;25(9):2097–2116.
11.
GilbertES. Ionizing radiation and cancer risks: what have we learned from epidemiology?Int J Radiat Biol. 2009;85(6):467–482.
12.
HankinsonSEDanforthKN. Ovarian cancer: SchottenfeldDFraumeniJr JF, eds. Cancer Epidemiology and Prevention, 3rd ed. New York, NY: Oxford University Press; 2006:1013e1026.
13.
ClappRWHoweGKJacobsMM. Environmental and occupational causes of cancer. A Review of Recent Scientific Literature. Lowell Center for Sustainable Production, University of Massachusetts, Lowell, 2005.
14.
KoutrosSLangsethHGrimsrudTK. Prediagnostic serum organochlorine concentrations and metastatic prostate cancer: a nested case-control study in the Norwegian Janus serum bank cohort. Environ Health Perspect. 2015;123(9):867–872.
15.
Garcia-PerezJLopeVLopez-AbenteGGonzalez-SanchezMFernandez-NavarroP. Ovarian cancer mortality and industrial pollution. Environ Pollut. 2015;205:103–110.
16.
RachonD. Endocrine disrupting chemicals and female cancer: informing the patients. Rev Endocr Metab Disord. 2015;16(4):359–364.
17.
AnnamalaiJNamasivayamV. Endocrine disrupting chemicals in the atmosphere: their effects on humans and wildlife. Environ Int. 2015;76:78–97.
IvanovaVDikovTDimitrovaN. Histologic subtypes of ovarian carcinoma: selected diagnostic and classification problems in Bulgaria: is low hospital volume an issue?Tumori. 2017;103(2):148–154. doi:10.5301/tj.5000571.
KarnezisANChoKRGilksCBPearceCLHuntsmanDG. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17(1):65–74.
22.
BairiKEKandhroAHGouriA. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell Oncol. 2017;40(2):105–118. doi:10.1007/s13402-016-0309-1.
23.
KurmanRJShihIM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
24.
WallbillichJJFordeBHavrileskyLJCohnDE. A personalized paradigm in the treatment of platinum-resistant ovarian cancer—a cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol Oncol. 2016;142(1):144–149.
25.
ChakravarthiBVNepalSVaramballyS. Genomic and epigenomic alterations in cancer. Am J Pathol. 2016;186(7):1724–1735.
26.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615.
ZaalAPeyrotWJBernsPM. Genomic aberrations relate early and advanced stage ovarian cancer. Cell Oncol. 2012;35(3):181–188.
29.
CaronO. Oncogenetics in the management of ovarian cancer: state-of-the art. Gynecol Obstet Fertil. 2015:43(5):335–337.
30.
PratJ. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237–249.
31.
NezhatFRApostolRNezhatCPejovicT. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262–267.
32.
ZhengWFadareO. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Pathol. 2012;5(3):182–186.
33.
AhmedAAEtemadmoghadamDTempleJ. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56.
34.
StreffHProfatoJYeY. Cancer incidence in first and second degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist. 2016;21(7):869–874.
MeiselCSadowskiCEKohlstedtD. Spectrum of genetic variants of BRCA1 and BRCA2 in a German single centre study. Arch Gynecol Obstet. 2017;295(5):1227–1238. doi:10.1007/s00404-017-4330-z.
37.
GorodetskaISergaSLahutaT. Prevalence of two BRCA1 mutations, 5382insC and 300T > G, in ovarian cancer patients from Ukraine [Published online March 11, 2017]. Fam Cancer. 2017. doi:10.1007/s10689-017-9978-9.
38.
KluskaABalabasAPiatkowskaM. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland. BMC Med Genomics. 2017;10(1):14. doi:10.1186/s12920-017-0251-8.
39.
ZuntiniRCortesiLCalistriD. BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. Oncotarget. 2017;8(14):22640–22648. doi:10.18632/oncotarget.15151.
40.
ZhangMZhuangGSunX. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer. Diagn Pathol. 2017;12(1):16.
41.
VangRLevineDASoslowRAZaloudekCShihIeMKurmanRJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a review of cases lacking TP53 mutations in the Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016;35(1):48–55.
42.
ChenSCavazzaEBarlierC. Besides P53 and PTEN: identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets. Oncol Lett. 2016;12(5):3264–3272.
43.
LuLWangJWuYWanPYangG. Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling. Cancer Med. 2016;5(12):3544–3554.
44.
RamusSJSongHDicksE. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst. 2015;107(11):djv214.
45.
McConechyMKDingJSenzJ. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014;27(1):128–134.
46.
NodinBZendehrokhNSundstromMJirstromK. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol. 2013;8:106.
RatajskaMAntoszewskaEPiskorzA. Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Res Treat. 2012;131(1):89–97.
49.
MeindlAHellebrandHWiekC. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410–414.
50.
MukhopadhyayAElattarACerbinskaiteA. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010;16(8):2344–2351.
51.
KuoKTMaoTLJonesS. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–1601.
52.
Szymanska-PasternakJSzymanskaAMedrekK. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol. 2006;102(3):429–431.
53.
Diamanti-KandarakisEBourguignonJPGiudiceLC. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev. 2009;30(4):293–342.
54.
GoreACChappellVAFentonSE. Executive summary to EDC-2: the endocrine society’s second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):593–602.
55.
KavlockRJDastonGPDeRosaC. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ Health Perspect. 1996;104(4):715–740.
56.
HugoERBrandebourgTDWooJGLoftusJAlexanderJWBen-JonathanN. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect. 2008;116(12):1642–1647.
57.
MeekerJDFergusonKK. Urinary phthalate metabolites are associated with decreased serum testosterone in men, women, and children from NHANES 2011–2012. J Clin Endocrinol Metab. 2014;99(11):4346–4352.
58.
ShahidehniaM. Epigenetic effects of endocrine disrupting chemicals. J Environ Anal Toxicol. 2016;6(4):381.
59.
SifakisSAndroutsopoulosVPTsatsakisAMSpandidosDA. Human exposure to endocrine disrupting chemicals: effects on the male and female reproductive systems. Environ Toxicol Pharmacol. 2017;51:56–70.
60.
ScsukovaSRollerovaEMlynarcikovaAB. Impact of endocrine disrupting chemicals on onset and development of female reproductive disorders and hormone-related cancer. Reprod Biol. 2016;16(4):243–254.
61.
ShanleEKXuW. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol. 2011;24(1):6–19.
62.
GaidoKWManessSCMcDonnellDPDehalSSKupferDSafeS. Interaction of methoxychlor and related compounds with estrogen receptor α and β, and androgen receptor: structure-activity studies. Mol Pharmacol. 2000;58(4):852-858.
63.
National Institute of Environmental Health Sciences. Endocrine disruptors. National Institute of Health, US Department of Health and Human Services; 2010. www.niehs.nih.gov. Accessed January 7, 2017.
64.
MaqboolFMostafalouSBahadarHAbdollahiM. Review of endocrine disorders associated with environmental toxicants and possible involved mechanisms. Life Sci. 2016;145:265–273.
65.
DeCosterSvan LarebekeN. Endocrine disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health. 2012;2012:713696.
66.
BraunJMKalkbrennerAEJustAC. Gestational exposure to endocrine-disrupting chemicals and reciprocal social, repetitive, and stereotypic behaviors in 4- and 5-year-old children: the HOME study. Environ Health Perspect. 2014;122(5):513–520.
67.
RemySGovartsEWensB. Metabolic targets of endocrine disrupting chemicals assessed by cord blood transcriptome profiling. Reprod Toxicol. 2016;65:307–320.
68.
VandenbergLNColbornTHayesTB. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012;33(3):378–455.
69.
DoganSSimsekT. Possible relationship between endocrine disrupting chemicals and hormone dependent gynecologic cancers. Med Hypotheses. 2016;92:84–87.
70.
KoutrosSAlavanjaMCLubinJH, JA. An update of cancer incidence in the agricultural health study. J Occup Environ Med. 2010;52(11):1098–1105.
71.
ClappRWJacobsMMLoechlerEL. Environmental and occupational causes of cancer new evidence, 2005-2007. Rev Environ Health. 2008;23(1):1–37.
72.
YoungHAMillsPKRiordanDGCressRD. Triazine herbicides and epithelial ovarian cancer risk in central California. J Occup Environ Med. 2005;47(11):1148–1156.
73.
LerroCCKoutrosSAndreottiG. Organophosphate insecticide use and cancer incidence among spouses of pesticide applicators in the agricultural health study. Occup Environ Med. 2015;72(10):736–744.
74.
KimJYYiBRGoREHwangKANamKHChoiKC. Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. Environ Toxicol Pharmacol. 2014;37(3):1264–1274.
75.
ParkSHKimKYAnBS. Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38. J Reprod Dev. 2009;55(1):23–29.
76.
AdewaleHBJeffersonWNNewboldRRPatisaulHB. Neonatal bisphenol-A exposure alters rat reproductive development and ovarian morphology without impairing activation of gonadotropin-releasing hormone neurons. Biol Reprod. 2009;81(4):690–699.
77.
PtakAWrobelAGregoraszczukEL. Effect of bisphenol-A on the expression of selected genes involved in cell cycle and apoptosis in the OVCAR-3 cell line. Toxicol Lett. 2011;202(1):30–35.
78.
PatelSZhouCRattanSFlawsJA. The effects of endocrine disrupting chemicals on the ovary. Bio Reprod. 2015;93(1):20.
79.
NishiKHundalSS. Chlorpyrifos induced toxicity in reproductive organs of female Wistar rats. Food Chem Toxicol. 2013;62:732–738.
80.
ZoellerRTBrownTRDoanLL. Endocrine disrupting chemicals and public health protection: a statement of principles from the endocrine society. Endocrinology. 2012;153(9):4097–4110.
81.
AmitaiIMatalonSTShochetGE. The effect of placental soluble factors and steroid hormones on ovarian cancer phenotype. Harefuah.2015;154(8):485–489.542.
82.
CrewsDMcLachlanJA. Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology. 2006;147(6):S4–S10.
83.
CostaEMFSpritzerPMHohlABachegaTASS. Effects of endocrine disruptors in the development of the female reproductive tract. Arq Bras Endocrinol Metab. 2014;58(2):153–161.
84.
ZamaAMUzumcuM. Epigenetic effects of endocrine-disrupting chemicals on female reproduction: an ovarian perspective. Front Neuroendocrinol. 2010;31(4):420–439.
85.
KojimaHKatsuraETakeuchiSNiiyamaKKobayashiK. Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect. 2004;112(5):524–531.
86.
WangHLiJGaoY. Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl. 2010;12(4):535–547.
87.
ParkMAHwangKALeeHRYiBRJeungEBChoiKC. Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models. Toxicology. 2013;305:41–48.
88.
Moyle-HeyrmanGSchipmaMJDeanMDavisDABurdetteJE. Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators. J Ovarian Res. 2016;9:5.
89.
MungenastFThalhammerT. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne). 2014;5:192.
90.
ShiLFWuYLiCY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause. 2016;23(4):417–424.
91.
TsilidisKKAllenNEKeyTJ. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2011;22(8):1075–1084.
92.
JordanSJWilsonLFNagleCM. Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy. Aust NZ J Public Health. 2015;39(5):434–440.
93.
TrabertBWentzensenNYangHP. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer. 2012;107(7):1181–1187.
94.
Collaborative group on epidemiological studies of ovarian cancer, BeralVGaitskellK. Menopausal hormone use and ovarian cancer risk: individual participant meta- analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835–1842.
95.
CramerDWVitonisAFTerryKLWelchWRTitusLJ. The association between talc use and ovarian cancer. A retrospective case–control study in two US states. Epidemiology. 2016;27(3):334–346.
96.
HallJMKorachKS. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL 12-CXCR4 signaling axis. Mol Carcinog. 2013;52(9):715–725.
97.
CardenasCAlveroABYunBSMorG. Redefining the origin and evolution of ovarian cancer: a hormonal connection. Endocr Relat Cancer. 2016;23(9):R411–R422.
98.
TomaoFRussoGLSpinelliGP. Fertility drugs, reproductive strategies and ovarian cancer risk. J Ovarian Res. 2014;7:51.
99.
ChoiJHWongASHuangHFLeungPC. Gonadotropins and ovarian cancer. Endocr Rev. 2007;28(4):440–461.
100.
RanceNE. Menopause and the human hypothalamus: evidence for the role of Kisspeptin/Neurokinin B neurons in the regulation of estrogen negative feedback. Peptides. 2009;30(1):111–122.
101.
SantoroN. Perimenopause: from research to practice. J Womens Health (Larchmt). 2016;25(4):332–339.
102.
GharwanHBuchKPAnnunziataCM. The role of reproductive hormones in epithelial ovarian carcinogenesis. Endocr Relat Cancer. 2015;22(6):R339–R363.
103.
CramerDWWelchWR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717–721.
104.
DiergaardeBKurtaML. Use of fertility drugs and risk of ovarian cancer. Curr Opin Obstet Gynecol. 2014;26(3):125–129.
105.
GoreAC. Organochlorine pesticides directly regulate gonadotropin-releasing hormone gene expression and biosynthesis in the GT1-7 hypothalamic cell line. Mol Cell Endocrinol. 2002;192(1-2):157–170.
106.
VenturaCNietoMRBourguignonN. Pesticide chlorpyrifos acts as an endocrine disruptor in adult rats causing changes in mammary gland and hormonal balance. J Steroid Biochem Mol Bio. 2016;156:1–9.
107.
MunierMGrouleffJGourdinL. In vitro effects of the endocrine disruptor p, p′- DDT on human follitropin receptor. Environ Health Perspect. 2016;124(7):991–999.
108.
ZhouWYangYXiongKLiuJ. Endocrine disrupting effects of dichlorodiphenyltrichloroethane analogues on gonadotropin hormones in pituitary gonadotrope cells. Environ Toxicol Pharmacol. 2014;37(3):1194–1201.
109.
LudwigAHMurawskaMPanekGTimorekAKupryjanczykJ. Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome. Endocr Relat Cancer. 2009;16(3):1005–1016.
110.
DanforthKNEliassenAHTworogerSS. The association of plasma androgen levels with breast, ovarian and endometrial cancer risk factors among postmenopausal women. Int J Cancer. 2010;126(1):199–207.
111.
CottreauCMNessRBModugnoFAllenGOGoodmanMT. Endometriosis and its treatment with danazol or lupron in relation to ovarian cancer. Clin Cancer Res. 2003;9(14):5142–5144.
TrisomboonJLiCSuzukiAWatanabeGTayaK. Nitro-3-phenylphenol has both androgenic and anti-androgenic-like effects in rats. J Reprod Dev. 2015;61(2):134–137.
114.
HernandezLHsuSCDavidsonBBirrerMJKohnECAnnunziataCM. Activation of NF-kB signaling by inhibitor of NF-kB kinase b increases aggressiveness of ovarian cancer. Cancer Res. 2010;70(10):4005–4014.
115.
KavandiLCollierMANguyenHSyedV. Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem. 2012;113(10):3143–3152.
116.
TakahashiAKatoKKuboyamaA. Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol. 2009;113(2):270–276.
117.
YangQDiamondMPAl-HendyA. Early life adverse environmental exposures increase the risk of uterine fibroid development: role of epigenetic regulation. Front Pharmacol. 2016;7:40.
118.
StrakovskyRSWangHEngesethNJ. Developmental bisphenol A (BPA) exposure leads to sex-specific modification of hepatic gene expression and epigenome at birth that may exacerbate high-fat diet-induced hepatic steatosis. Toxicol Appl Pharmacol. 2015;284(2):101–112.
119.
HamidiTSinghAKChenT. Genetic alterations of DNA methylation machinery in human diseases. Epigenomics. 2015;7(2):247–265.
120.
ListerRPelizzolaMDowenRH. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315–322.
121.
GopalakrishnanSVan EmburghBORobertsonKD. DNA methylation in development and human disease. Mutat Res. 2008;647(
1-2
):30–38.
122.
TaberlayPCJonesPA. DNA methylation and cancer. In: GasserSMLiE, eds. Epigenetics and Disease, Pharmaceutical Opportunities. Switzerland: Springer Basel AG; 2011:1–5.
123.
WongRLYWalkerCL. Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Clin Cancer Res. 2013;19(14):3732–3737.
124.
SkinnerMK. Endocrine disruptor induction of epigenetic transgenerational inheritance of disease. Mol Cell Endocrinol. 2014;398(1-2):4–12.
125.
JirtleRLSkinnerMK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8(4):253–262.
126.
BlewittMWhitelawE. The use of mouse models to study epigenetics. Cold Spring Harb Perspect Biol. 2013;5(11):a017939.
127.
CisnerosFJ. DNA methylation and male infertility. Front Biosci. 2004;9:1189–1200.
128.
AnwayMDCuppASUzumcuMSkinnerMK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005;308(5727):1466–1469.
129.
KortenkampA. Are cadmium and other heavy metal compounds acting as endocrine disrupters?Met Ions Life Sci. 2011;8:305–317.
130.
KnowerKCToSQLeungYHoSClyneCD. Endocrine disruption of the epigenome: a breast cancer link. Endocr Relat Cancer. 2014;21(2):T33–T55.
131.
RomagnoloDFDanielsKDGrunwaldJTRamosSAPropperCRSelminOI. Epigenetics of breast cancer: modifying role of environmental and bioactive food compounds. Mol Nutr Food Res. 2016;60(6):1310–1329.
132.
ZamaAMUzumcuM. Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes. Endocrinology. 2009;150(10):4681–4691.
133.
AhluwaliaAHurteauJABigsbyRMNephewKP. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 2001;82(2):299–304.
134.
UzumcuMZamaAMOrucE. Epigenetic mechanisms in the actions of endocrine- disrupting chemicals: gonadal effects and role in female reproduction. Reprod Domest Anim. 2012;47(4):338–347.
135.
YoonKKwackSJKimHSLeeBM. Estrogenic endocrine disrupting chemicals: molecular mechanisms of actions on putative human diseases. J Toxicol Environ Health B Crit Rev. 2014;17(3):127–174.
136.
HeindelJJZoellerRT. Endocrine disrupting chemicals and human diseases. In: JamesonJLDe GrootLJ, eds. Endocrinology: Adult and Pediatric, 7th ed. US: Elsevier Health, 2016:2640–2652.
137.
OrphanidesGReinbergD. A unified theory of gene expression. Cell. 2002;108(4):439–451.
138.
FormanDBrayFBrewsterDH. Cancer incidence in five continents. Vol. X. Lyon, France: International Agency for Research on Cancer. IARC Scientific Publications No. 164; 2014.
139.
Economist Intelligence Unit. Breakaway: The global burden of cancer-challenges and opportunities. London, UK: The Economist; 2009.
140.
EjazSAkramWLimCWLeeJJHussainI. Endocrine disrupting pesticides: a leading cause of cancer among rural people in Pakistan. Exp Oncol. 2004;26(2):98–105.
BenckoV. Human exposure to endocrine disruptors: carcinogenic risk assessment. Folia Histochem Cytobiol. 2001;39(2):24–25.
143.
HeijmansBTTobiEWLumeyLHSlagboomPE. The epigenome: archive of the prenatal environment. Epigenetics. 2009;4(8):526–531.
144.
FowlerPABellinghamMSinclairKD. Impact of endocrine disrupting compounds (EDCs) on female reproductive health. Mol cell Endocrinol. 2012;355(2):231–239.
145.
GrindlerNMAllsworthJEMaconesGAKannanKRoehlKACooperAR. Persistent organic pollutants and early menopause in US women. PLoS One. 2015;10(1):e0116057.
146.
DavisKRFlowerKJBorleyJVWilhelm-BenartziCSM. Cell-free circulating tumor DNA methylation in high-grade serous ovarian cancer. Cancer Res. 2016;76 (14 Supplement):3154–3154.
147.
ValleBLKuhnESidranskyDGuerrero-PrestonR. DNA promoter hypermethylation of genes as potential diagnostic and prognostic biomarkers for ovarian cancer. Cancer Res. 2015;75 (15 Supplement):2960–2960.
148.
DobrovicAMikeskaTAlsopK. Constitutional BRCA1 methylation is a major predisposition factor for high-grade serous ovarian cancer. Cancer Res. 2014;74 (19 Supplement):290–290.
149.
GlossBSSamimiG. Epigenetic biomarkers in epithelial ovarian cancer. Cancer Lett. 2014;342(2):257–263.
